AU2022223692A1 - Compositions comprising 4-1bb and ox40 binding proteins and methods of use - Google Patents

Compositions comprising 4-1bb and ox40 binding proteins and methods of use Download PDF

Info

Publication number
AU2022223692A1
AU2022223692A1 AU2022223692A AU2022223692A AU2022223692A1 AU 2022223692 A1 AU2022223692 A1 AU 2022223692A1 AU 2022223692 A AU2022223692 A AU 2022223692A AU 2022223692 A AU2022223692 A AU 2022223692A AU 2022223692 A1 AU2022223692 A1 AU 2022223692A1
Authority
AU
Australia
Prior art keywords
amino acid
seq
antigen
acid sequence
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022223692A
Other languages
English (en)
Inventor
David Leonard BIENVENUE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptevo Research and Development LLC
Original Assignee
Aptevo Research and Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptevo Research and Development LLC filed Critical Aptevo Research and Development LLC
Publication of AU2022223692A1 publication Critical patent/AU2022223692A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022223692A 2021-02-17 2022-02-17 Compositions comprising 4-1bb and ox40 binding proteins and methods of use Pending AU2022223692A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150475P 2021-02-17 2021-02-17
US63/150,475 2021-02-17
PCT/US2022/016776 WO2022178114A1 (en) 2021-02-17 2022-02-17 Compositions comprising 4-1bb and ox40 binding proteins and methods of use

Publications (1)

Publication Number Publication Date
AU2022223692A1 true AU2022223692A1 (en) 2023-09-21

Family

ID=80738990

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022223692A Pending AU2022223692A1 (en) 2021-02-17 2022-02-17 Compositions comprising 4-1bb and ox40 binding proteins and methods of use

Country Status (8)

Country Link
US (1) US20240150483A1 (cg-RX-API-DMAC10.html)
EP (1) EP4294843A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024508746A (cg-RX-API-DMAC10.html)
KR (1) KR20230167025A (cg-RX-API-DMAC10.html)
CN (1) CN117203236A (cg-RX-API-DMAC10.html)
AU (1) AU2022223692A1 (cg-RX-API-DMAC10.html)
CA (1) CA3208339A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022178114A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120584137A (zh) 2023-01-06 2025-09-02 阿帕特夫研究和发展有限公司 双特异性pd-l1和cd40结合分子以及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO2005063291A1 (ja) * 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
BR112017024770A2 (pt) * 2015-05-21 2018-07-31 Alligator Bioscience Ab polipeptídeos inovadores
NZ757965A (en) * 2017-03-16 2022-07-01 Lg Chemical Ltd Liquid formulation of anti-tnf alpha antibody
AU2019301206B2 (en) * 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
JP7539897B2 (ja) * 2019-01-16 2024-08-26 コンパス セラピューティクス リミテッド ライアビリティ カンパニー ヒトcd137に結合する抗体の製剤およびその使用
MX2022001882A (es) * 2019-08-12 2022-05-30 Aptevo Res & Development Llc Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.

Also Published As

Publication number Publication date
CA3208339A1 (en) 2022-08-25
US20240150483A1 (en) 2024-05-09
EP4294843A1 (en) 2023-12-27
WO2022178114A1 (en) 2022-08-25
JP2024508746A (ja) 2024-02-28
CN117203236A (zh) 2023-12-08
KR20230167025A (ko) 2023-12-07

Similar Documents

Publication Publication Date Title
AU2022259766B2 (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
KR102742528B1 (ko) 항-bcma 중쇄-단독 항체
US20230235071A1 (en) Anti-CD30 Antibodies and Methods for Treating CD30+ Cancer
KR20180040671A (ko) Bcma와 cd3에 결합하는 이중특이성 항원 결합 분자인 항-bcma 항체, 및 이들의 용도
RU2746314C2 (ru) Антитела анти-tnfrsf25
US20230192854A1 (en) Anti-btla antibody pharmaceutical composition and use thereof
JP2011523414A (ja) 抗fn14抗体、およびその使用
US20240075133A1 (en) Methods and compositions for reduction of immunogenicity
KR20210063467A (ko) Edb 표적화 il-12 조성물
JP2024059913A (ja) がんの併用療法
CN116615253A (zh) 与叶酸受体α结合的重链抗体
WO2020165374A1 (en) Bifunctional molecule comprising il-15ra
US20240150483A1 (en) COMPOSITIONS COMPRISING 4-1BB and OX40 BINDING PROTEINS AND METHODS OF USE
US20250368738A1 (en) Anti-cd28 antibodies
JP7691138B2 (ja) 4-1bbおよび0x40結合タンパク質ならびに関連する組成物および方法、4-1bbに対する抗体、0x40に対する抗体
WO2025098341A1 (en) IL-7Ra TARGETING ANTIBODIES AND USES THEREOF
WO2025235357A1 (en) Bispecific antibodies that bind to cd28 and nectin-4
JP2025515325A (ja) 抗ilt4抗体又はその抗原結合フラグメントの医薬製剤及び使用方法
JP2023551907A (ja) 腫瘍関連抗原及びcd3結合タンパク質、関連する組成物、及び方法
HK40078517A (en) 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
EA045980B1 (ru) Антитела против рецептора полиовируса (pvr) и их применение
EA043164B1 (ru) Способы и композиции для снижения иммуногенности